On 28 June 2006 the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of the marketing authorisation for the medicinal product Alpheon 6 million IU/ml solution for injection intended for the treatment of hepatitis C. The company that applied for authorisation is BioPartners GmbH. It may request a re-examination of the opinion within 15 days of receipt of notification of this negative opinion.
recombinant human interferon alfa-2a
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
Hepatitis C, Chronic
|Anatomical therapeutic chemical (ATC) code||
|Date of opinion||
|Date of refusal of marketing authorisation||